Combiner pour mieux traiter - ACHAT - OC 14,3€
Suite à son partenariat avec la société chinoise Tasly, nous initions la couverture de Pharnext avec un objectif de cours de 14,3€ (+61%vs le dernier cours côté). Pharnext a mis au point une approche innovante de développement de médicament : PLEOTHERAPY™. Celle-ci consiste à créer de nouveaux traitements en combinant et repositionnant des molécules, dont la cible thérapeutique est connue, à de nouvelles doses optimales plus faibles. Le pipeline de la société est composé de 2 actifs dans 4 indications. PXT3003, 1er produit de la société, est actuellement en Phase 3 dans la maladie de CMT1A. Les premiers résultats devraient tomber au T3 18 (analyse de futilité au T4 17).Pharnext SA is a France-based biopharmaceutical company. The Company is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The Company's prime focus is on neurodegenerative diseases and metabolic diseases.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.